Beyond Sativex: GW Launches Cannabinoid Cancer Clinical Program

By Nuala MoranStaff Writer

Monday, November 11, 2013

LONDON – GW Pharmaceuticals plc has advanced its expertise in cannabis pharmacology to the next stage, starting the first formal clinical trial of a cannabinoid as an antitumor therapeutic. “There is a lot of preclinical evidence in the literature, but in terms of clinical development, this is the first time a natural cannabinoid has been tested in cancer,” said Justin Gover, CEO.